Back Back
Expert Think Tank on <i>EGFR</i>m NSCLC: Module

CE / CME

Expert Think Tank: Lung Cancer Experts Discuss Current Standard of Care and Ongoing Challenges in the Care of Patients With EGFR-Mutated NSCLC

Pharmacists: 1.25 contact hours (0.125 CEUs)

Nurses: 1.25 Nursing contact hours

Physicians: Maximum of 1.25 AMA PRA Category 1 Credits™

Released: September 30, 2022

Expiration: September 29, 2023

Edward B Garon
Edward B Garon, MD, MS
Xiuning Le
Xiuning Le, MD, PhD
Zofia Piotrowska
Zofia Piotrowska, MD
Mark A. Socinski
Mark A. Socinski, MD
Helena Yu
Helena Yu, MD
CME/CE Information

Activity

Progress
1
Course Completed

Edward B. Garon, MD, MS:
In closing, I would like to thank our panelists for a robust discussion of our HCP survey data and their expert perspectives on the management of NSCLC with EGFR mutations. We covered many interesting questions on recent progress in the molecular characterization of EGFR mutations and available treatments for patients with NSCLC harboring various EGFR alterations. We have come a long way since when I had to send patients home with stage IV NSCLC, an Eastern Cooperative Oncology Group performance status of 0, and EGFR mutations because there were no treatments available. Now, we are subdividing lung cancer into a host of different groups based on their specific molecular drivers, and as we saw with EGFR, even looking for atypical groupings within a particular molecular driver. These are exciting and encouraging developments for our patients now, and as we introduced in the discussion of future directions, we will continue to see in the years to come.

BACK | NEXT